Gemmus Pharma to Present New Data at 26th Annual International Society for Antiviral Research (ICAR) Meeting in San Francisco, May 13
4/22/2013 6:33:38 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Gemmus Pharma Inc. ("Gemmus") will present results from its initial studies designed to evaluate the use of GP1001 in influenza at the 26th International Conference on Antiviral Research (ICAR) in San Francisco on May 13 in the afternoon session. The talk, titled “GP1001: a host targeted influenza therapy,” will be given by Daryl Faulds, Ph.D., Co-Founder and Chief Executive Officer of Gemmus, a privately held drug development company.
Help employers find you! Check out all the jobs and post your resume.
comments powered by